Drug
Ak129
Ak129: highest development phase Phase 1/2, developed by Akeso. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK129 NCT06642792 | Phase 1/2 | Classic Hodgkin Lymphoma |
Latest
No recent events.
Follow Ak129 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.